101 related articles for article (PubMed ID: 9304078)
1. [Hormone replacement therapy (HRT). The effects at 12 months on the risk factors for menopausal osteoporosis].
Camilli A; Di Benedetto L; Camilli FM; Ermini M
Minerva Ginecol; 1997 May; 49(5):193-8. PubMed ID: 9304078
[TBL] [Abstract][Full Text] [Related]
2. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of the climacteric symptomatology modifications and clinical-instrumental parameters in women in physiological menopause treated with hormone replacement therapy with nomegestrol acetate and in surgical menopause treated with estrogen replacement therapy. Part I].
Savoca S; D'Agosta S; Lombardo G
Minerva Ginecol; 2007 Jun; 59(3):205-14. PubMed ID: 17576399
[TBL] [Abstract][Full Text] [Related]
4. Nomegestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover in menopausal women after a 12-week treatment period.
Nguyên-Pascal ML; Thomas JL; Bergougnoux L; Garnero P; Drapier-Faure E; Delmas PD
Climacteric; 2005 Jun; 8(2):136-45. PubMed ID: 16096169
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the dose of hormone replacement therapy.
Rice VM
Int J Fertil Womens Med; 2002; 47(5):205-10. PubMed ID: 12469707
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the hematochemical parameters and bone mineral density of women in physiological menopause treated with hormone replacement therapy with nomegestrol acetate and surgical menopause treated with estrogen replacement. Part II].
Savoca S; D'Agosta S; Lombardo G
Minerva Ginecol; 2007 Jun; 59(3):215-22. PubMed ID: 17576400
[TBL] [Abstract][Full Text] [Related]
7. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate.
Neven P; Lunde T; Benedetti-Panici P; Tiitinen A; Marinescu B; de Villiers T; Hillard T; Cano A; Peer E; Quail D; Nickelsen T;
BJOG; 2003 Feb; 110(2):157-67. PubMed ID: 12618160
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
9. [Effect of low calcitonin doses on bone remodeling in postmenopausal women with high bone turnover rate].
Campusano C; López JM; Campino C; Cárdenas I; Rojas A
Rev Med Chil; 2000 Apr; 128(4):387-91. PubMed ID: 10962855
[TBL] [Abstract][Full Text] [Related]
10. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
Burger H
Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
[TBL] [Abstract][Full Text] [Related]
11. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
Brodowska A
Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
[TBL] [Abstract][Full Text] [Related]
12. Postmenopausal osteoporosis and hormone replacement therapy.
Gambacciani M; Vacca F
Minerva Med; 2004 Dec; 95(6):507-20. PubMed ID: 15785435
[TBL] [Abstract][Full Text] [Related]
13. [Hormone replacement therapy with 17 beta-estradiol dydrogesterone: results of a 3-month open-label study].
Grisar J; Travica S; Metka M; Pietschmann P
Wien Klin Wochenschr; 1999 Dec; 111(24):1035-43. PubMed ID: 10677891
[TBL] [Abstract][Full Text] [Related]
14. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
[TBL] [Abstract][Full Text] [Related]
15. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
[TBL] [Abstract][Full Text] [Related]
16. L-thyroxin treatment and post-menopausal osteoporosis: relevance of the risk profile present in clinical history.
La Vignera S; Vicari E; Tumino S; Ciotta L; Condorelli R; Vicari LO; Calogero AE
Minerva Ginecol; 2008 Dec; 60(6):475-84. PubMed ID: 18981975
[TBL] [Abstract][Full Text] [Related]
17. Climacteric: concept, consequence and care.
Taechakraichana N; Jaisamrarn U; Panyakhamlerd K; Chaikittisilpa S; Limpaphayom KK
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S1-15. PubMed ID: 12188398
[TBL] [Abstract][Full Text] [Related]
18. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
19. Comparison of zinc excretion and biochemical markers of bone remodelling in the assessment of the effects of alendronate and calcitonin on bone in postmenopausal osteoporosis.
Gur A; Colpan L; Cevik R; Nas K; Jale Sarac A
Clin Biochem; 2005 Jan; 38(1):66-72. PubMed ID: 15607319
[TBL] [Abstract][Full Text] [Related]
20. [The effects of hormone replacement therapy (HRT) on lipid metabolism in the menopause].
Camilli A; Di Benedetto L; Camilli FM; Ermini M
Minerva Ginecol; 1997 May; 49(5):199-202. PubMed ID: 9304079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
